- Poster presentation
- Open Access
0995. Aspirin reduces neutrophilic pulmonary inflammation in a human model of acute respiratory distress syndrome induced by inhaled lipopolysaccharide
© Hamid et al; licensee Springer. 2014
- Published: 26 September 2014
- Pulmonary Oedema
- Acute Respiratory Distress Syndrome
- Human Model
- Pulmonary Inflammation
Acute respiratory distress syndrome (ARDS) is characterized by damage to the alveolar epithelial-endothelial barrier resulting in neutrophil influx and pulmonary oedema. The activation of platelet and secondary capture of neutrophils may play an important role in propagation of inflammation in ARDS . Various animal studies have shown that aspirin therapy reduces pulmonary oedema and development of lung injury . In observational studies, patients on aspirin therapy prior to hospital admission had a reduced incidence of ARDS . By acetylating cyclooxygenase, aspirin inhibits platelet aggregation and generates anti-inflammatory molecules which modulate neutrophilic inflammation .
To test the hypothesis that aspirin reduces pulmonary inflammation in an in vivo human model of acute respiratory distress syndrome, induced by inhaled lipopolysaccharide (LPS).
Healthy subjects were enrolled in a double-blind, placebo-controlled study and were randomised to receive aspirin 75mg or aspirin 1200mg or placebo (1:1:1) for seven days prior to LPS inhalation. Measurements were performed in bronchoalveolar lavage (BAL) fluid obtained at 6 hours after inhaling 50 micrograms of LPS.
healthy subjects were enrolled. There was no significant difference between aspirin 75mg and aspirin 1200mg. Data for both aspirin groups were combined. Aspirin pre-treatment reduced LPS induced BAL neutrophilia (figure 1) and BAL concentrations of both the neutrophil-specific protease MMP-8, and the pro-inflammatory cytokine TNF-α. There was a non-significant trend towards reduction in a range of inflammatory cytokines (table 1).
Effect of aspirin on markes of pulmonary inflammation
2.25 (1.18, 4.67)
1.48 (0.32, 6.21)
105.7 (73.49, 358.5)
79.72 (37.34, 276.6)
856.5 (535.9, 2285)
647.9 (224.6, 1582)
6342 (1932, 9574)
2902 (862.8, 6758)
48493 (23126, 99780)
33717 (10471, 72334)
447.5 (236.9, 1250)
345.9 (175.5, 1522)
42.74 (25.98, 98.76)
37.03 (18.73, 54.88)
This study shows for the first time that aspirin can reduce neutrophilic inflammation in the lung in humans. Further clinical studies are warranted to assess its ability to reduce neutrophil mediated inflammation in ARDS.
This work was funded by the UK Intensive Care Society.
ClinicalTrials.gov identifier: NCT01659307.
- Kuebler WM: J Clin Invest. 2006,116(12):3106–8. 10.1172/JCI30664PubMed CentralPubMedView ArticleGoogle Scholar
- Looney MR, et al.: J Clin Invest. 2009,119(11):3450–61.PubMed CentralPubMedGoogle Scholar
- Erlich JM, et al.: Chest. 2011,139(2):289–95. 10.1378/chest.10-0891PubMed CentralPubMedView ArticleGoogle Scholar
- Filep JG, et al.: Prostaglandins Leukot Essent Fatty Acids. 2005,73(3–4):257–62. 10.1016/j.plefa.2005.05.014PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.